CTLA4 and cancer: To date, clinical trials with cancer immunotherapy molecules such as anti-PD-1 and anti-CTLA-4 ended with disappointing outcomes, emphasizing the need for combination therapies that focus on multiple immune cells and checkpoint markers to treat tumors of patients who do not respond to single agent therapies [15, 16].